Adipokines play a significant role in the pathogenesis of a low-grade inflammation associated with obesity and metabolic syndrome, and in chronic inflammatory and autoimmune diseases such as rheumatoid arthritis. Among variety of adipokines, resistin and visfatin are proposed as important pro-inflammatory mediators, which also interfere with the central regulation of insulin sensitivity. Resistin has been initially postulated as a risk factor for insulin resistance, however, the subsequent available data on it have revealed contradictory findings in both humans and rodents. On the other hand, visfatin has been suggested to be a beneficial adipokine with insulin-mimicking/-sensitizing effects, but regulation of visfatin production and its physiological importance in the conditions of obesity and type 2 diabetes mellitus are still not completely understood. Despite the opposing effects of resistin and visfatin on the regulation of insulin sensitivity, both adipokines have pro-inflammatory properties. Clinical and experimental studies have shown that the expression and secretion of resistin and visfatin are up-regulated during inflammation and in response to pro-inflammatory cytokines. It has also become increasingly evident that resistin as well as visfatin itself can contribute to the inflammatory processes by triggering cytokine production and NF-kappaB activation. New insight into the role of adipokines makes them attractive targets for novel therapeutic strategies in chronic inflammatory diseases or subclinical inflammation relating to obesity and various metabolic abnormalities.

Department of Normal Pathological and Clinical Physiology 3rd Faculty of Medicine Charles University Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12025926

003      

CZ-PrNML

005      

20130101195711.0

007      

ta

008      

120817s2010 xo f 000 0#eng||

009      

AR

024    7_

$a 10.4149/endo_2010_01_25 $2 doi

035    __

$a (PubMed)20151765

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xo

100    1_

$a Štofková, Andrea. $7 xx0246901 $u Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University in Prague, Czech Republic. andrea.stofkova@lf3.cuni.cz

245    10

$a Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity / $c A. Stofkova

520    9_

$a Adipokines play a significant role in the pathogenesis of a low-grade inflammation associated with obesity and metabolic syndrome, and in chronic inflammatory and autoimmune diseases such as rheumatoid arthritis. Among variety of adipokines, resistin and visfatin are proposed as important pro-inflammatory mediators, which also interfere with the central regulation of insulin sensitivity. Resistin has been initially postulated as a risk factor for insulin resistance, however, the subsequent available data on it have revealed contradictory findings in both humans and rodents. On the other hand, visfatin has been suggested to be a beneficial adipokine with insulin-mimicking/-sensitizing effects, but regulation of visfatin production and its physiological importance in the conditions of obesity and type 2 diabetes mellitus are still not completely understood. Despite the opposing effects of resistin and visfatin on the regulation of insulin sensitivity, both adipokines have pro-inflammatory properties. Clinical and experimental studies have shown that the expression and secretion of resistin and visfatin are up-regulated during inflammation and in response to pro-inflammatory cytokines. It has also become increasingly evident that resistin as well as visfatin itself can contribute to the inflammatory processes by triggering cytokine production and NF-kappaB activation. New insight into the role of adipokines makes them attractive targets for novel therapeutic strategies in chronic inflammatory diseases or subclinical inflammation relating to obesity and various metabolic abnormalities.

650    _2

$a zvířata $7 D000818

650    _2

$a autoimunita $7 D015551

650    _2

$a lidé $7 D006801

650    _2

$a zánět $x imunologie $x metabolismus $x patofyziologie $7 D007249

650    _2

$a mediátory zánětu $x metabolismus $7 D018836

650    _2

$a inzulin $x metabolismus $7 D007328

650    _2

$a inzulinová rezistence $7 D007333

650    _2

$a nikotinamidfosforibosyltransferasa $x metabolismus $7 D054409

650    _2

$a resistin $x metabolismus $7 D052243

650    _2

$a signální transdukce $7 D015398

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

773    0_

$w MED00001518 $t Endocrine regulations $x 1210-0668 $g Roč. 44, č. 1 (2010), s. 25-36

856    41

$u https://pubmed.ncbi.nlm.nih.gov/20151765 $y Pubmed

910    __

$a ABA008 $b A 3699 $c 152 a $y m

990    __

$a 20120817 $b ABA008

991    __

$a 20130101195856 $b ABA008

999    __

$a ok $b bmc $g 947968 $s 783272

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2010 $b 44 $c 1 $d 25-36 $i 1210-0668 $m Endocrine regulations $n Endocr. Regul. $x MED00001518

LZP    __

$a Pubmed-20120817/10/03